Moderna: letter to shareholders reviews 2024

(CercleFinance.com) - Moderna has published a letter to shareholders written by its CEO, Stéphane Bancel.
NB: pmt +4.7%.

In this letter, Moderna announces that 2024 was marked by major challenges and notable advances, especially in its development pipeline.

The company won approval for mRESVIA, its RSV vaccine for older adults, becoming a multi-product company with two mRNA vaccines on the market.

Moderna also reports four positive Phase 3 results in its respiratory portfolio, and has advanced several non-pulmonary programs, including a norovirus vaccine and therapies for rare diseases.

Despite increased competition for the COVID-19 vaccine, the company anticipates a sustainable long-term market. Moderna adds that it has reduced its operating costs by 25% in 2024, and plans to further reduce its R&D expenditure by 2027.

The company has also strengthened its management team and collaborated with OpenAI to optimize its operations through AI.


Copyright (c) 2025 CercleFinance.com. All rights reserved.